Treatment of Osteoporosis

Osteoporosis represents a serious societal problem generating numerous health and social complications as well as considerable economic costs. In the Czech Republic, it is estimated to affect 500−750 thousand people, or 5−7% of the population. From January 1, 2024, the prescription restriction for the indication and reimbursement conditions for the medicinal products Osagrand (ibandronic acid) and Risendros (risedronic acid) will be lifted, allowing general practitioners to prescribe them as well, under the prescription conditions listed…